UPK2 Antibody

1. Uroplakin II was immunopositive in 53% and 60% of urothelial carcinomas (UC) of the bladder and the ureter, respectively. PMID: 30061246
2. These results suggest that whereas GATA-3 and uroplakin II may be most useful in the diagnosis of urothelial carcinoma metastasis, p40 may be additionally suited as a prognostic marker. PMID: 27594510
3. UPII, GATA3, and p40, when used in combination, are highly sensitive in the differential diagnosis of invasive urothelial carcinoma. PMID: 25611245
4. UPII was highly specific/moderately sensitive for urothelial carcinoma. May be a potentially useful marker to identify urothelial lineage and help distinguish UC from prostate cancer or, in conjunction with GATA3, from metastatic breast cancer. PMID: 25449628
5. UPII demonstrates a significantly higher sensitivity than UPIII in conventional and variant urothelial carcinomas PMID: 25389341
6. Uroplakin II antibody BC21 demonstrated superior sensitivity and specificity in urothelial carcinoma, compared with uroplakin III, suggesting an advantage in differential diagnosis of urothelial carcinoma and in the detection of tumors of unknown origin. PMID: 24978921
7. combination of prostate stem cell antigen enhancer and uroplakin II promoter is feasible in constructing bladder cancer-specific vectors PMID: 18440837
8. study offers no definitive support for uroplakin II mutations causing human renal tract malformations PMID: 17012268

Show More

Hide All

HGNC: 12579

OMIM: 611558

KEGG: hsa:7379

STRING: 9606.ENSP00000264031

UniGene: Hs.379613